Clinical trials: Hepatitis b Virus
Chronic Hepatitis Delta Virus Infection
A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05861674
- Testing
- HH-003(20mg/kg), HH-003(10mg/kg), TAF
- Where
- 7 sites in China, Pakistan
- Volunteers
- 101 people
- Sponsor
- Huahui Health
Chronic Hepatitis B Virus (HBV) Infection
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
This Phase 2, randomized, double-blind study will evaluate the clinical efficacy and safety of the combination therapy of BRII-179, BRII-835, plus PEG-IFNα compared to PEG-IFNα in adult participants with chronic HBV infection…
- Trial name
- NCT06650852
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 14 sites in China
- Volunteers
- 250 people
- Sponsor
- Brii Biosciences Limited
For Treatment of Chronic Hepatitis B Virus Infection
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
This study will evaluate the efficacy and safety of the regimens containing BRII-179, BRII-835, and PEG-IFNα in adult participants with chronic hepatitis B virus (HBV) infection receiving nucleos(t)ide reverse transcriptase…
- Trial name
- NCT06491563
- Testing
- BRII-179, BRII-835 (VIR-2218), PEG-IFNα
- Where
- 12 sites in China
- Volunteers
- 150 people
- Sponsor
- Brii Biosciences Limited
Chronic Hepatitis B Virus
A Clinical Study of AHB-121 in Healthy Participants and Chronic Hepatitis B (CHB) Participants
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AHB-121 injection in healthy and chronic hepatitis B participants.
- Trial name
- NCT07884864
- Testing
- AHB-121
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Hepatitis B Virus Infection
Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients
This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
- Trial name
- NCT05970289
- Testing
- PEG-IFNα, BRII-835
- Where
- 28 sites in Australia, China and 3 more
- Volunteers
- 86 people
- Sponsor
- Brii Biosciences Limited
Hepatitis B, Chronic
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-201 (NCT07370207)
- Testing
- AHB-137
- Where
- 10 sites in Australia, China and 5 more
- Volunteers
- 84 people
- Sponsor
- AusperBio Therapeutics Inc.
Chronic Hepatitis B Virus Infection
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV).
- Trial name
- NCT07389044
- Testing
- IB-001, Peginterferon Alfa-2A
- Where
- 5 sites in Hong Kong, Moldova and 2 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- IntegerBio
Hepatitis B Virus Infection
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
- Trial name
- NCT07024641
- Testing
- GIGA-2339
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 48 people
- Sponsor
- GigaGen, Inc.
Hepatitis B, Chronic
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-202 (NCT07654283)
- Testing
- AHB-137
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- AusperBio Therapeutics Inc.
Chronic Hepatitis B Virus Infection, Hepatitis B
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy.
- Trial name
- B-UNITED (NCT06537414)
- Testing
- Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen
- Where
- 80 sites in United States, Australia and 17 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
- Trial name
- NCT07037277
- Testing
- Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
- Where
- 107 sites in Egypt, France and 15 more
- Volunteers
- 880 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Chronic Hepatitis B Virus Infection
Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection
Study HH006-202 is designed to assesses the efficacy and safety of HH-006 in adults chronic HBV infection. Eligible participants will receive study treatment for 48 weeks.
- Trial name
- NCT07519330
- Testing
- HH-006
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Huahui Health
Chronic Hepatitis Delta Virus Infection
Expanded Access for Bulevirtide
The goal of this study is to provide access to bulevirtide (BLV (GS-4438), Hepcludex®) to eligible participants with chronic hepatitis delta virus infection (CHD).
- Trial name
- NCT06780579
- Testing
- Bulevirtide
- Sponsor
- Gilead Sciences
Hepatitis C Virus (HCV)
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
- Trial name
- NCT07419347
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AbbVie
Chronic Hepatitis B Virus Infection
A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients
This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of…
- Trial name
- NCT07515209
- Testing
- HH-006, 0.9% normal saline
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Huahui Health
HEPATITIS C VIRUS CHRONIC INFECTION
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
- Trial name
- NCT06868264
- Testing
- Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL)
- Where
- 105 sites in United States, Canada
- Volunteers
- 880 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis Delta Virus, Hepatitis D
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants
This study is designed to assess safety, tolerability, and pharmacokinetics of single ascending doses (SAD) and multiple-ascending doses (MAD) of ABI-6250 in healthy participants. Effect of food will also be evaluated in Part A.
- Trial name
- NCT06740474
- Testing
- ABI-6250
- Where
- New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Chronic Hepatitis C Virus, Hepatitis C, Chronic
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
This is an open-label trial to evaluate safety and efficacy of treatment with BEM + RZR in subjects with chronic HCV infection.
- Conditions
- Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis
- Trial name
- NCT05904470
- Testing
- Bemnifosbuvir, Ruzasvir
- Where
- 51 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Atea Pharmaceuticals, Inc.
Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B
The objective of this study was to evaluate the efficacy and safety of TVAX-008 Injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial in NAs-treated subjects with chronic…
- Trial name
- NCT07190742
- Testing
- TVAX-008
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Hepatitis C Virus (HCV)
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
This study will assess the safety and effectiveness of Maviret (Glecaprevir plus Pibrentasvir (GLE/PIB)) in adolescent participants diagnosed with chronic hepatitis C (CHC) in a real world setting across clinical practice in…
- Trial name
- NCT04214028
- Where
- 54 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AbbVie